DMRA — Damora Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Galecto Announces Positive Preliminary Results For Oral Galectin-3 Inhibitor GB1211 In Part 1 Of Its Phase 1b/2a Liver Cirrhosis Trial
Brief: Galecto Reports Q3 Operating And Financial Results
Brief: Galecto Inc Files For Mixed Shelf Of Up To $200 Million – SEC Filing
Brief: Galecto To Collaborate With Roche For Phase 2 Trial Of Lung Cancer Treatment
Brief: Galecto Says First Patient Treated In Phase 2 Trial Of Oral Galectin-3 Inhibitor GB1211 In Liver Cirrhosis
Brief: Galecto Announces First Patient Treated In Phase 2A Trial Of The Oral Loxl2 Inhibitor Gb2064 In Myelofibrosis (The Mylox-1 Trial)
Galecto Inc reports results for the quarter ended in June - Earnings Summary
Brief: Galecto Reports Second Quarter Operating And Financial Results
Brief: Galecto Resumes Recruitment In Phase 2B Global GALACTIC-1 Trial Of GB0139
Brief: Galecto’S Gb0139 Shows Favorable Safety And Tolerability Profile With Promising Changes In Efficacy Markers In Hospitalized Covid-19 Patients
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:44 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:07 PM
Brief: Galecto Q1 Loss Per Share $0.53
U.S. RESEARCH ROUNDUP- East West Bancorp, Genmark Diagnostics, iHeartMedia
Brief: Galecto Announces Outcome Of Data Safety Monitoring Board Interim Review Of Phase 2B Galactic-1 Study Of Gb0139
Brief: Galecto Inc. says Increased Board Size To Nine Directors And Appointed Anne Prener To Join Board
Brief: Galecto Appoints Anne Prener To Its Board Of Directors
Brief: Galecto Inc- As Of Dec 31, 2020 Co's Cash, Cash Equivalents And Investments Balance Was About $164 Mln
Brief: Galecto Reports Third-Quarter Results, Provides Corporate Update